Semaglutide 10mg

As a glucagon-like peptide-1 receptor agonist (GLP-1 RA), it increases the secretion of the hormone insulin which helps the cells to effectively utilize energy. This process ensures proper fat storage and decreases blood glucose (blood sugar) levels. Semaglutide also suppresses your appetite and slows gastric emptying by blocking certain chemicals in the brain. This in turn helps promote fat loss. Semaglutide is important for long-term weight management due to its efficacy in promoting significant and sustained weight loss in adults with obesity. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide works by mimicking the effects of the GLP-1 hormone, which regulates appetite and food intake. [1] The once-weekly injectable formulation of semaglutide has shown remarkable results in clinical trials, demonstrating greater weight loss compared to placebo and other weight-loss medications. By enhancing feelings of fullness, reducing hunger, and slowing down gastric emptying, semaglutide helps individuals achieve meaningful and durable weight reduction, making it a promising and valuable option for managing chronic weight issues and improving overall health outcomes.

How Semaglutide Works for Weight Loss Semaglutide promotes weight loss by: Reducing Appetite: It slows down the movement of food through the stomach (gastric emptying) and helps regulate the hunger centers in the brain, leading to a feeling of fullness and reducing cravings. Improving Insulin Sensitivity: Semaglutide helps manage blood sugar levels by stimulating insulin release when glucose levels are elevated. Decreasing Caloric Intake: Because it reduces hunger, patients often consume fewer calories, leading to gradual and sustained weight loss.

Drucker D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001 Wilding, J., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989. https://doi.org/10.1056/NEJMoa2032183 Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., Wilding, J., &Rubino, D. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring, Md.), 28(6), 1050–1061. https://doi.org/10.1002/oby.22794 Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., &Kiortsis, D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity reviews : an official journal of the International Association for the Study of Obesity, 20(6), 805–815. https://doi.org/10.1111/obr.12839 Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators (2021). Effect of Continued Weekly Subcutaneous Semaglutidevs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224